Over the past few months, COVID-19, the pandemic disease caused by severe acute respiratory syndrome coronavirus 2, has been associated with a high rate of infection and lethality, especially in patients with comorbidities such as obesity, hypertension, diabetes, and immunodeficiency syndromes.1 These cardiometabolic and immune impairments are common comorbidities of Cushing’s syndrome, a condition characterised by excessive exposure to endogenous glucocorticoids. In patients with Cushing’s syndrome, the increased cardiovascular risk factors, amplified by the increased thromboembolic risk, and the increased susceptibility to severe infections, are the two leading causes of death.

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess / Pivonello, R.; Ferrigno, R.; Isidori, A. M.; Biller, B. M. K.; Grossman, A. B.; Colao, A.. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - 8:8(2020), pp. 654-656. [10.1016/S2213-8587(20)30215-1]

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess

Pivonello R.
;
Isidori A. M.;
2020

Abstract

Over the past few months, COVID-19, the pandemic disease caused by severe acute respiratory syndrome coronavirus 2, has been associated with a high rate of infection and lethality, especially in patients with comorbidities such as obesity, hypertension, diabetes, and immunodeficiency syndromes.1 These cardiometabolic and immune impairments are common comorbidities of Cushing’s syndrome, a condition characterised by excessive exposure to endogenous glucocorticoids. In patients with Cushing’s syndrome, the increased cardiovascular risk factors, amplified by the increased thromboembolic risk, and the increased susceptibility to severe infections, are the two leading causes of death.
2020
cushing's disease; COVID-19; cardiovascular risk; infections
01 Pubblicazione su rivista::01f Lettera, Nota
COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess / Pivonello, R.; Ferrigno, R.; Isidori, A. M.; Biller, B. M. K.; Grossman, A. B.; Colao, A.. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - 8:8(2020), pp. 654-656. [10.1016/S2213-8587(20)30215-1]
File allegati a questo prodotto
File Dimensione Formato  
Pivonello_Covid-19_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 50.32 kB
Formato Adobe PDF
50.32 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1557019
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact